10028 Federal Register / Vol. 66, No. 30 / Tuesday, February 13, 2001 / Notices

recombination system for chromosome

engineering in Escherichia coli,’’

P.N.A.S. 97(11):5978–5983 (2000).

Simian-Human HAV Chimeras

Encoding a Hepatitis A Virus Having a

Chimeric 2C Protein

G Raychaudhuri, SU Emerson, RH

Purcell (NIAID)

Serial No. 60/015,642 filed 19 Apr 1996;

PCT/US97/06506 filed 18 Apr 1997;

Serial No. 09/171,387 filed 24 Mar

1999

Licensing Contact: Carol Salata, 301/

496–7735 ext. 232; e-mail:

salatac@od.nih.gov.

The claimed invention provides

nucleic acid sequences which encode

hepatitis A viruses having a chimeric 2C

protein. The chimeric 2C gene consists

of sequences from both the human

strain and the simian AGM–27 strain.

The chimeric virus is a promising

candidate for an attenuated hepatitis A

virus vaccine which may be more

economical than an inactivated vaccine,

especially in underdeveloped countries

where hepatitis A in endemic.

Additional information on the chimeras

may be found in Rayachaudhuri et al.,

‘‘Utilization of chimeras between

human(HM175) and simian(AGM27)

strains of hepatitis A virus to study the

molecular basis of virulence,’’ J. Virol.

72:7467–7474(1998).

Novel Antimalarial Compounds,

Methods of Synthesis Thereof,

Pharmaceutical Compositions

Comprising Same, and Methods of

Using Same for Treatment and

Prevention of Malaria

Michael R. Boyd (NCI), Gerhard

Bringmann (EM), Sven Harmsen (EM)

Roland Gotz (EM), T. Ross Kelly (EM),

Matthias Wenzel (EM), Guido

Francois (EM), J. D. Phillipson (EM),

Laurent A. Assi (EM), Christopher

Schneider (EM) Serial No. 08/195,547,

filed 02/14/1994, now U.S. Patent

5,639,761; Serial No. 08/843,582, filed

04/16/1997; Serial No. 08/279,261,

filed 07/22/1994, now U.S. Patent

5,552,550; Serial No. 08/674,362, filed

07/01/1996, now U.S. Patent

5,763,613; Serial No. 09/001,801, filed

12/31/1997, now U.S. Patent

6,140,339; Serial No. 09/527,002, filed

03/16/2000; Serial No. 08/279,339,

filed 07/22/1994, now U.S. Patent

5,571,919; Serial No. 08/363,684, filed

12/23/1994, now U.S. Patent

5,578,729; Serial No. 08/674,359, filed

07/01/1996, now U.S. Patent

5,789,594; Serial No. 08/721,084, filed

09/24/1996, now U.S. Patent

5,786,482

Licensing Contact: Peter Soukas; 301/

496–7056 ext. 268; e-mail:

soukasp@od.nih.gov.

According to data recently reported

by the World Health Organization

(WHO), the death rate from malaria

exceeds one million individuals per

year. The Public Health Service seeks

exclusive or non-exclusive licensee(s) to

develop and commercialize the

technology claimed within the portfolio

of U.S. patents issued and pending, and

corresponding international patents

issued and pending. These patents and

pending applications claim an

exceptionally broad universe of novel

naphthylisoquinoline alkaloid

compounds, and methods of total

synthesis thereof. Representative

examples of these compounds have

been shown to have potent in vitro

activity against malaria parasites,

including parasites that are highly

resistant to available antimalarial drugs.

Representative examples have also been

shown to have potent in vivo activity

against malaria parasites in animal

models. Pharmaceutical compositions

comprising these compounds, as well as

methods of using the compounds to

treat or prevent a malarial infection of

a host, are claimed. The relative

structural simplicity of this class of

compounds, and the ready synthetic

access thereto, provide unprecedented

opportunities for structure-activity

relationship (SAR), lead-optimization

and antimalarial drug development. The

technology is further described in the

following publications: J. Nat Prod. 1997

Jul.;60(7):677–83 and Bioorg. Med.

Chem. Lett. 1998 Jul.;8(13): 1729–34.

Dated: February 2, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 01–3605 Filed 2–12–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated licensing contact at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

The ImmunoChip

Matthias Lorenz (NCI)

DHHS Reference No. E–288–00/0 filed

29 Dec 2000

Licensing Contact: Richard Rodriguez;

301/496–7056 ext. 287; e-mail:

rodrigur@od.nih.gov.

The inventors have established a

method to select sequences from

databases for the construction of custom

microarrays. Using this method, an

immunological relevant microarray

(ImmunoChip) was constructed. The

ImmunoChip is a cDNA microarray

which contains more than 13,000

different murine immunologicalrelevant genetic probes. The

ImmunoChip can be used to study gene

expression of immune cells or immune

infiltrating tissues and organs.

Specifically, the chip could be used for

immunologically related research and/

or vaccine development for a variety of

human diseases which would include,

but not necessarily limited to, cancer,

infectious diseases, autoimmune

diseases and allergies.

Water Soluble Amino Acid Analogs of

Aminoflavone Compounds

Kenneth M. Snader et al. (NCI)

DHHS Reference No. E–279–99/0 filed

06 Apr 2000

Licensing Contact: Girish Barua; 301/

496–7735 ext. 263; e-mail:

baruag@od.nih.gov.

Many potential drugs of cancer

chemotherapy intended for parenteral

administration have been abandoned

because the active ingredient is either

slightly soluble or water-insoluble.

Various methods have been developed

to improve water solubility of these

drugs. However, these methods can be

complex and have a negative impact

resulting from the use of co-solvents and

complexing agents. The present

invention addresses these problems by

providing a method of producing waterVerDate 11<MAY>2000 17:06 Feb 12, 2001 Jkt 194001 PO 00000 Frm 00022 Fmt 4703 Sfmt 4703 E:\FR\FM\13FEN1.SGM pfrm08 PsN: 13FEN1
Federal Register / Vol. 66, No. 30 / Tuesday, February 13, 2001 / Notices 10029

soluble analogues of water-insoluble

drugs.

In particular, the present invention

describes novel analogues derived from

5-aminoflavone (TK2339) compounds.

These derivatives have shown good

differential activity in the NCI 60-cell

line in vitro cancer drug screen with

potent and selective cytotoxicity against

CAKI–1 and A498 renal, MCF–7 breast,

and OVCAR–5 ovarian carcinoma cell

lines. In addition, these derivatives have

shown in vivo activity against CAKI–1

and A498 renal carcinoma xenographs.

To overcome poor solubility of many

members of the flavone class of

compounds, a series of more

hydrophilic, polar conjugates were

prepared which are capable of forming

soluble salts. These novel compounds

display improved solubility in aqueous

solutions over the parent compound

without sacrificing potent antitumor

activity. Since these compounds possess

very favorable pharmaceutical

properties, they have the greater

potential to be useful in the treatment of

human cancers.

Dated: February 2, 2001.

Jack Spiegel,

Director, Division of Technology,

Development and Transfer, Office of

Technology Transfer, National Institutes of

Health.

[FR Doc. 01–3606 Filed 2–12–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Dental &

Craniofacial Research; Notice of

Closed Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute of

Dental and Craniofacial Research Special

Emphasis Panel 01–33, Review of R13

Grants.

Date: February 16, 2001.

Time: 11 a.m. to 1 p.m.

Agenda: To review and evaluate grant

applications.

Place: 45 Center Drive, Natcher Building,

Conference Room E1⁄2, Bethesda, MD 20892,

(Telephone Conference Call).

Contact Person: H. George Hausch, PhD,

Chief, 4500 Center Drive, Natcher Building,

Rm. 4AN44F, National Institutes of Health,

Bethesda, MD 20892, (301) 594–2372.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: National Institute of

Dental and Craniofacial Research Special

Emphasis Panel 01–34, Review of training

grants.

Date: February 21–22, 2001.

Time: 2 p.m. to 4 p.m.

Agenda: To review and evaluate grant

applications.

Place: The Hyatt Regency Hotel, 100

Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: Yujing Liu, MD, PhD,

Scientific Review Administrator, National

Institute of Dental & Craniofacial Res., 45

Center Drive, Natcher Building, Rm. 4AN44F,

Bethesda, MD 20892, (301) 594–2372.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: National Institute of

Dental and Craniofacial Research Special

Emphasis Panel 01–24, Review of R13

Grants.

Date: February 28, 2001.

Time: 10 a.m. to 12 p.m.

Agenda: To review and evaluate grant

applications.

Place: 45 Center Drive, Bethesda, MD

20892, (Telephone Conference Call).

Contact Person: H. George Hausch, PhD,

Chief, 4500 Center Drive, Natcher Building,

Rm. 4AN44F, National Institutes of Health,

Bethesda, MD 20892, (301) 594–2372,

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: National Institute of

Dental and Craniofacial Research Special

Emphasis Panel 01–25, Review of R01s.

Date: April 5, 2001.

Time: 2 p.m. to 4 p.m.

Agenda: To review and evaluate grant

applications.

Place: 45 Center Drive, Bethesda, MD

20892, (Telephone Conference Call).

Contact Person: Yasaman Shirazi, PhD,

Scientific Review Administrator, 4500 Center

Drive, Natcher Building, Rm. 4AN44F,

National Institute of Dental & Craniofacial

Res., Bethesda, MD 20892, (301) 594–2372.

Name of Committee: National Institute of

Dental and Craniofacial Research Special

Emphasis Panel 01–28, Review of R44

Grants.

Date: April 6, 2001.

Time: 1 p.m. to 3 p.m.

Agenda: To review and evaluate grant

applications.

Place: 45 Center Drive, Bethesda, MD

20892, (Telephone Conference Call).

Contact Person: Philip Washko, PhD, DMD,

Scientific Review Administrator, 45 Center

Drive, Natcher Building, Rm. 4AN44F,

National Institutes of Health, Bethesda, MD

20892, (301) 594–2372.

Name of Committee: National Institute of

Dental and Craniofacial Research Special

Emphasis Panel 01–17, Review of R01

Grants.

Date: April 11, 2001.

Time: 1 p.m. to 3 p.m.

Agenda: To review and evaluate grant

applications.

Place: 45 Center Drive, Bethesda, MD

20892, (Telephone Conference Call).

Contact Person: Philip Washko, PhD, DMD,

Scientific Review Administrator, 45 Center

Drive, Natcher Building, Rm. 4AN44F,

National Institutes of Health, Bethesda, MD

20892, (301) 594–2372.

Name of Committee: National Institute of

Dental and Craniofacial Research Special

Emphasis Panel.

Date: April 24, 2001.

Time: 1 p.m. to 2:30 p.m.

Agenda: To review and evaluate grant

applications.

Place: 45 Center Drive, Bethesda, MD

20892, (Telephone Conference Call).

Contact Person: Philip Washko, PhD, DMD,

Scientific Review Administrator, 45 Center

Drive, Natcher Building, Rm. 4AN44F,

National Institutes of Health, Bethesda, MD

20892, (301) 594–2372.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.121, Oral Diseases and

Disorders Research, National Institutes of

Health, HHS)

Dated: February 6, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–3593 Filed 2–12–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Dental &

Craniofacial Research; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.